Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective Phase II study of Dose-Adjusted EPOCH-R (NCT01092182), which showed that the vast majority of patients with Burkitt’s Lymphoma achieved complete remission with the DA-EPOCH-R based therapy. The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
The DA-EPOCH-R clinical trial in Burkitt’s lymphoma
13th June 2016
Hematology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?